Fuan Pharmaceutical Group Co Market Cap ($640.66 Million)
Market Cap & Net Worth: Fuan Pharmaceutical Group Co (300194)
Fuan Pharmaceutical Group Co market cap. Fuan Pharmaceutical Group Co (SHE:300194) has a market capitalization of $640.66 Million (CN¥4.38 Billion) as of November 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #10644 globally and #2825 in its home market, demonstrating a -1.87% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Fuan Pharmaceutical Group Co's stock price CN¥3.68 by its total outstanding shares 1189712382 (1.19 Billion). Also see Fuan Pharmaceutical Group Co operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Fuan Pharmaceutical Group Co Market Cap History (2015–2026)
Fuan Pharmaceutical Group Co market cap history from 2015 to 2026. Data shows change from $1.02 Billion to $640.66 Million (-4.11% CAGR). Check today's stock price for Fuan Pharmaceutical Group Co for real-time trading data and today's change.
Fuan Pharmaceutical Group Co Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Fuan Pharmaceutical Group Co's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Fuan Pharmaceutical Group Co to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.44x
Fuan Pharmaceutical Group Co's market cap is 0.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
10.02x
Fuan Pharmaceutical Group Co's market cap is 10.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.42 Billion | $1.30 Billion | $221.96 Million | 1.10x | 6.40x |
| 2017 | $939.80 Million | $2.09 Billion | $284.81 Million | 0.45x | 3.30x |
| 2018 | $534.24 Million | $2.67 Billion | -$359.98 Million | 0.20x | N/A |
| 2019 | $922.01 Million | $2.78 Billion | $292.83 Million | 0.33x | 3.15x |
| 2020 | $828.09 Million | $2.37 Billion | $209.37 Million | 0.35x | 3.96x |
| 2021 | $869.68 Million | $2.45 Billion | -$296.91 Million | 0.35x | N/A |
| 2022 | $611.50 Million | $2.42 Billion | $204.61 Million | 0.25x | 2.99x |
| 2023 | $753.00 Million | $2.65 Billion | $231.87 Million | 0.28x | 3.25x |
| 2024 | $776.45 Million | $2.39 Billion | $279.84 Million | 0.32x | 2.77x |
| 2025 | $771.23 Million | $1.74 Billion | $77.00 Million | 0.44x | 10.02x |
Competitor Companies of 300194 by Market Capitalization
Companies near Fuan Pharmaceutical Group Co in the global market cap rankings as of November 4, 2026. Also see balance sheet size of Fuan Pharmaceutical Group Co for a full breakdown of the balance sheet.
Key companies related to Fuan Pharmaceutical Group Co by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #534 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #580 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #534 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.90 |
| #580 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.03 Billion | CN¥49.31 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Fuan Pharmaceutical Group Co (2015–2026)
Market capitalization of Fuan Pharmaceutical Group Co from 2015 to today. Between 2015 and today, Fuan Pharmaceutical Group Co's market cap moved from $1.02 Billion to $ 640.66 Million, with a yearly change of -4.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥640.66 Million | -16.93% |
| 2025 | CN¥771.23 Million | -0.67% |
| 2024 | CN¥776.45 Million | +3.11% |
| 2023 | CN¥753.00 Million | +23.14% |
| 2022 | CN¥611.50 Million | -29.69% |
| 2021 | CN¥869.68 Million | +5.02% |
| 2020 | CN¥828.09 Million | -10.19% |
| 2019 | CN¥922.01 Million | +72.58% |
| 2018 | CN¥534.24 Million | -43.15% |
| 2017 | CN¥939.80 Million | -33.88% |
| 2016 | CN¥1.42 Billion | +39.59% |
| 2015 | CN¥1.02 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Fuan Pharmaceutical Group Co was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $640.66 Million USD |
| MoneyControl | $640.66 Million USD |
| MarketWatch | $640.66 Million USD |
| marketcap.company | $640.66 Million USD |
| Reuters | $640.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Fuan Pharmaceutical Group Co
Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China and internationally. It offers APIs; intermediates; and FDFs, such as anti-tumor, specialty drugs, antibiotics, as well as freeze-drying preparation for injection. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) … Read more